Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Flexibility Is Key, Say German Cross-Party MPs In Rebuff To EU's Harmonized HTA

Executive Summary

Industry in various parts of Europe has privately voiced doubts about the practicalities of an EU-wide health technology assessment system for medical devices, and now MPs in Germany – once again politically ready after the successful completion of marathon government coalition talks – have officially opposed the idea.

You may also be interested in...



German Medtech Industry Takes Aim At EU-Wide HTA Bid

The EU Council is scheduled to debate the European Commission's EU-wide health technology assessment proposal today, but opposition to the concept within medtech circles has started to mount, notably in Germany.

Expert Analysis: EU Commission's Proposed Regulation On Health Technology Assessment

An HTA proposal from the European Commission represents a new step toward harmonized market access for health technologies in the EU. Simmons & Simmons lawyers Annabelle Bruyndonckx and Vladimir Murovec provide an expert view on the proposal, its impact on the medtech sector and how it relates to the EU Medical Device and IVD Regulations.

Revolutionary EU HTA Cooperation Proposal Will Use MDR/IVDR Platforms

The European Commission wants to rationalize health technology assessment work across the EU, and new EU medtech regulations offer an easy way to determine which products can benefit from joint clinical assessments.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT122444

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel